ZYBERNO
Stock Report
Updated Jun 6, 2026

ADAPTIMMUNE THERAPEUTICS PLC (ADAP)

Healthcare • NASDAQ

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
13.0/100
POOR BUSINESS
ADAPTIMMUNE THERAPEUTICS PLC (ADAP) scores 13/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-117.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ADAPTIMMUNE THERAPEUTICS PLC (ADAP) stock report — Zyberno Score 13/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ADAP generated -$109.84M in Owner Earnings. Capital was deployed as follows: $1.99M invested in capital expenditures. Reinvestment rate: 8.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$3.49M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$7.61M
B. Profitability Assessment

Return Metrics (4)

ROA:-79.7%
Reinvestment Rate:8.1%
Fundamental Growth Rate (g):-9.5%

Margin Analysis (1)

Ebitda Margin:-83.0%

Yield Metrics (2)

Earnings Yield:-$5.00K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-142.1%
Latest Earnings Filed:2025-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):42.1%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.52x
Quick Ratio:1.29x
Cash Ratio:0.51x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-15.36x
Times Interest Earned:-15.36

Capital Structure (4)

Working Capital:26,602,000.00
Cash And Cash Equivalents:26,061,000.00
Long Term Debt:$25.68M
Net Debt:$4.13M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $178.03M
Linear Growth: 42.1%
📊 Click to view full ADAP Revenue analysis & methodology →
Cost Of Revenue Ttm:$70.00K

Profitability Breakdown (2)

$177.96M-$164.22M

Bottom Line Performance (3)

-$169.76M
Income Before Tax:-$166.05M
Ebitda Ttm:-147,721,000.00

Operating Expenses (5)

Operating Expenses:229,305,000.00
R And D Expense:125,241,000.00
Sga Expense:90,213,000.00
Income Tax Expense:$3.71M
Interest Expense:4,478,000.00

Expense Ratios (3)

R And D To Revenue Percentage:915.7%
Sga To Revenue Percentage:659.6%
Ebitda Margin:-83.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$130.63M
Current Assets:$78.12M
Ppe Net:28,152,000.00
Goodwill:0.00
Intangible Assets:$3.81M

Liability Structure (4)

Total Liabilities:201,591,000.00
Current Liabilities:51,513,000.00
Long Term Debt:$25.68M
Short Term Debt:$4.51M

Equity & Capital (3)

Equity:-$70.96M
Retained Earnings:-$1.17B
Common Stock:2,108,130,546.00

Working Capital Items (3)

Accounts Receivable:9,313,000.00
Inventory:11,411,000.00
Accounts Payable:9,418,000.00

Special Items (2)

Contract Liabilities:112,119,000.00
Stock Based Compensation:1,321,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$107.85M-$109.84M

Investment Activities (2)

Investing Cash Flow:$41.15M
Capital Expenditures Ttm:1,987,000.00

Financing Activities (3)

Financing Cash Flow:-$25.32M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:122,000.00
Long Term Debt Issuance:$49.50M
Long Term Debt Repayments:$25.45M

Non-Cash Items (1)

Depreciation Amortization Ttm:16,499,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.12
-$0.11
Earnings Per Share Ttm:-$0.11

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.11
Operating Cash Flow Per Share:-$0.05

Book Value & Capital (2)

Book Value Per Share:-$0.04
Cash Per Share:0.02

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.84x
Working Capital Turnover Ttm:6.69x

Receivables Management (2)

Receivables Turnover Ttm:19.12x
Days Sales Outstanding Ttm:19.09

Inventory Management (2)

Inventory Turnover Ttm:0.01x
Days Inventory Outstanding Ttm:59,500.21

Payables & Cash Cycle (2)

Days Payable Outstanding:49,108.14
Cash Conversion Cycle:10,411.16
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$109.84M

Damodaran Growth Analysis (2)

Reinvestment Rate:8.1%
Fundamental Growth Rate (g):-9.5%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):42.1%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-46.5%
C. Company Profile & Context

Corporate Information (6)

Symbol:ADAP
Company Name:ADAPTIMMUNE THERAPEUTICS PLC
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:1.58B
Shares Outstanding Basic:1.58B
Shares Outstanding Diluted:1.58B

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-06 05:35:00 UTC
Data Timestamp:2026-06-06T05:35:00.172838
Scroll to Top